Evidence map›Paper›PMID 40835455›Full record

ArticleRNA (New York, N.Y.)2025

Pseudouridine residues as substrates for serum ribonucleases.

Clair S Gutierrez, Bjarne Silkenath, Volga Kojasoy, Jaroslaw A Pich, Daniel C Lim, Ronald T Raines

Abstract read
In one paragraph

Article in RNA (New York, N.Y.), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. NNature · 2026
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Clair S Gutierrez *Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.ORCID 0000-0001-9235-7223
Bjarne Silkenath *Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.ORCID 0000-0001-9862-6076
Volga Kojasoy *Department of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.ORCID 0000-0003-4832-0479
Jaroslaw A PichDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.ORCID 0009-0008-5670-8696
Daniel C LimDepartment of Biology, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA.ORCID 0000-0002-8861-4837
Ronald T RainesDepartment of Chemistry, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA rtraines@mit.edu.ORCID 0000-0001-7164-1719

Funding

RIBONUCLEASES IN CANCER THERAPYR01CA073808 · NCI · UNIVERSITY OF WISCONSIN-MADISON · PI RAINES, RONALD T · 1997 to 2024
$7.3M
NCI NIH HHS R01 CA073808
6 · The paper itself

Abstract

In clinical uses, RNA must maintain its integrity in serum that contains ribonucleases (RNases), especially RNase 1, which is a human homolog of RNase A. These omnipresent enzymes catalyze the cleavage of the P-O

Indexed as

PseudouridineRibonuclease, PancreaticCrystallography, X-RayHumansMolecular Dynamics SimulationRNASubstrate SpecificityPseudouridineRibonuclease, PancreaticRNAenzymologyinductive effectmolecular dynamics simulationsnucleoside 2′,3′-cyclic vanadateX-ray crystallography

Identifiers

PMID40835455
PMCPMC12530130

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.